Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cessatech ASXSAT:CESSA +4.84%30 Cash Ratio is 3.85 as of Mar. 2026, which is 35% below its 10-year median of 5.91. GuruFocus rates XSAT:CESSA with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,355 Biotechnology companies, Cessatech AS ranks better than 56.53% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Cessatech AS Cash Ratio Related Terms
Cessatech AS Cash Ratio Historical Data
* Premium members only.
The historical data trend for Cessatech AS's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:CESSA vs VRTX, REGN, RVMD: Cash Ratio Comparison
For the Biotechnology subindustry, Cessatech AS's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cessatech AS Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cessatech AS's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Cessatech AS's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cessatech AS (XSAT:CESSA) has a Cash Ratio of 3.85 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cessatech AS and its competitors. This is 35% below median its historical median of 5.91. Over the past decade, Cessatech AS's Cash Ratio has ranged from 0.32 to 68.56. According to the industry distribution chart, Cessatech AS ranks #589 out of 1355 companies in the Biotechnology industry, placing it in the top 43.5%.
Is Cessatech AS's Cash Ratio too high?
Cessatech AS's current Cash Ratio of 3.85 is 35% below median its 10-year median of 5.91. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 68.56. The Biotechnology industry median Cash Ratio is 2.96. Cessatech AS's value of 3.85 is 30.1% above this industry median. Based on the distribution chart, Cessatech AS ranks #589 out of 1355 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cessatech AS has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Cessatech AS's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cessatech AS ranks #589 out of 1355 companies for Cash Ratio. This puts Cessatech AS in the upper half of its industry. The industry median Cash Ratio is 2.96. Cessatech AS's value of 3.85 is 30.1% above this benchmark. Historically, Cessatech AS's own Cash Ratio has ranged from 0.32 to 68.56 over the past decade. While the company's 10-year median is 5.91 vs. the industry median of 2.96, Cessatech AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,355 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cessatech AS's current Cash Ratio of 3.85 is 30.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cessatech AS and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cessatech AS's current Cash Ratio is 3.85, which is 35% below median its own 10-year median of 5.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cessatech AS stock overvalued right now?
Cessatech AS (XSAT:CESSA) has a current Cash Ratio of 3.85. The current Cash Ratio is 3.85, which is 35% below median its 10-year median of 5.91 and 30.1% above the Biotechnology industry median of 2.96. Cessatech AS's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Cessatech AS (XSAT:CESSA), the current Cash Ratio is 3.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based medicines for children for the treatment of paediatric acute pain. The company is advancing a pipeline comprising three assets, all addressing an unmet medical need in the treatment of children. The main candidate, CT001, a fixed-dose nasal spray for treating acute pain in children, is in the pre-launch phase in the U.S. and the EU. CT002, a non-invasive intranasal sedation for children undergoing medical procedures (e.g., MRI scans), has an approved PIP in the EU. CT003, a topical anaesthetic, is currently in pre-clinical development.
30GF Score
Get the complete analysis for XSAT:CESSA
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:CESSA has been successfully added to your 
